The global Aptamers Market size is expected to reach USD 10.9 billion by 2030, according to a new report by Grand View Research Inc. The market is expected to expand at a CAGR of 23.5% from 2022 to 2030. The growth of the market is attributed to the strong presence of product pipelines and their expected launch during the forecast period. Some of the products in the pipeline are E10030 (Fovista), ARC1905 (Zimura) by IVERIC Bio, Inc., AGRO100 by Antisoma Research Ltd, NOX-A12 (olaptesed pegol) & NOX-E36 (emapticap pegol) by NOXXON Pharma, and NU172 by ARCA Biopharma, Inc. AGRO100 completed the phase 1 clinical trial for multiple oncology indications such as non-small cell lung cancer, solid tumors, and renal cancer.

In addition, initiatives undertaken by regulatory agencies such as the U.S. FDA, Health Canada, EMA, COFEPRIS, MHRA, and CDSCO to support the research and development in the field of aptamers are projected to fuel market growth. For instance, in March 2020, IVERIC Bio, Inc. received Fast Track designation from the U.S. FDA for Zimura for the treatment of patients with GA secondary to age-related macular degeneration (AMD). Zimura is a chemically synthesized pegylated RNA aptamer, administered by intravitreal injection. It acts by inhibiting complement factor C5 which is responsible for the development of AMD.

Companies are studying aptamers for applications such as western blotting, ELISA, therapeutics, and flow cytometry. Custom aptamer selection is considered to be an important service offered by existing aptamer players to life sciences companies. Thrombin aptamers, cocaine aptamers, and theophylline aptamers are some of the most frequently used customized aptamers for research and development activities. Thus, the surge in numbers of biotech and pharma companies working on research related to aptamers and related technologies has opened up new avenues for the growth of this market.

Moreover, there are a number of strategic initiatives undertaken by key players such as mergers & acquisitions, with an aim to expand their current aptamer product portfolio. For instance, in May 2022, Epicore Biosystems acquired Eccrine Systems' intellectual property and assets. This acquisition boosts Epicore’s wearable microfluidic solutions with additional aptamer-based sweat sensor technology from the Eccrine Systems and the University of Cincinnati to its aptamer product portfolio and strengthens the company’s position in the market. This aptamers-based sensor has been demonstrated in stress, pain, and other healthcare management applications.

Related Press Release@ Aptamers Market Report

Aptamers Market Report Highlights

• The nucleic acid aptamers segment dominated the market in 2021. The segment is set to grow at a rapid pace into areas such as therapeutics, diagnostics, research and development consumables, and biomarker discovery
• The research and development segment dominated the market in 2021 due to the growing interest of companies in aptamers; moreover, the rising awareness level coupled with favorable government initiatives are expected to stimulate the market growth of this applications segment during the study period
• The diagnostics segment is expected to be the fastest-growing segment during the forecast period due to the rising demand for aptamer-based diagnostic kits for the early diagnosis of diseases. For instance, in July 2021, SomaLogic and the CM Life Sciences announced the supply of 7,000-plex SomaScan Assay kits & SomaScan data to Beth Israel Deaconess Medical Center (BIDMC) for proteomics research
• North America dominated the market in 2021 due to the presence of key biopharmaceutical companies such as SomaLogic, IVERIC Bio, Inc., Aptagen LLC, Base Pair Biotechnologies, and their strategic initiatives for the development of new aptamers